- Home
- ADIL vs BLRX Comparison
ADIL vs BLRX Comparison
Compare ADIL & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADIL | BLRX |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2M | 11.7M |
| IPO Year | 2017 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ADIL | BLRX |
|---|---|---|
| Price | $4.18 | $1.99 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.33 | N/A |
| AVG Volume (30 Days) | ★ 31.6K | 13.3K |
| Earning Date | 11-12-2026 | 11-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $37.33 |
| Revenue Next Year | N/A | $37.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.13 | $1.95 |
| 52 Week High | $9.53 | $3.95 |
Technical Indicators
Market Signals| Indicator | ADIL | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.37 | 38.56 |
| Support Level | $3.80 | $1.95 |
| Resistance Level | $4.94 | $2.56 |
| Average True Range (ATR) | 0.36 | 0.17 |
| MACD | 0.10 | 0.00 |
| Stochastic Oscillator | 65.00 | 28.57 |
Price Performance
Historical ComparisonAbout ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.